{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:13:22Z","timestamp":1792034002286,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejps.2025.107340","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:23:50Z","timestamp":1760999030000},"page":"107340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A risk-based, QTPP-driven framework for semi-solid extrusion 3d printing of personalized medicines: Integrating hospital compounding and clinical trial regulation"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-2516","authenticated-orcid":false,"given":"Maxime","family":"Annereau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5838-3695","authenticated-orcid":false,"given":"Philippe-Henri","family":"Secretan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107340_bib0001","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/pharmaceutics16091212","article-title":"Real-world evidence of 3D printing of personalised paediatric medicines and evaluating its potential in children with cancer: a scoping review","volume":"16","author":"Ahmed","year":"2024","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejps.2025.107340_bib0002","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s11095-016-1933-1","article-title":"Emergence of 3D printed dosage forms: opportunities and challenges","volume":"33","author":"Alhnan","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107340_bib0003","unstructured":"ANSM, 2023. Bonnes pratiques de pr\u00e9paration [WWW Document]. ANSM. URL https:\/\/ansm.sante.fr\/documents\/reference\/bonnes-pratiques-de-preparation (accessed 8.13.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0004","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijpharm.2018.07.024","article-title":"3D printed medicines: a new branch of digital healthcare","volume":"548","author":"Awad","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107340_bib0005","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.drudis.2018.05.025","article-title":"Reshaping drug development using 3D printing","volume":"23","author":"Awad","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2025.107340_bib0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41205-022-00134-y","article-title":"Interpretation of regulatory factors for 3D printing at hospitals and medical centers, or at the point of care","volume":"8","author":"Beitler","year":"2022","journal-title":"3D. Print. Med."},{"key":"10.1016\/j.ejps.2025.107340_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124306","article-title":"Developing an innovative 3D printing platform for production of personalised medicines in a hospital for the OPERA clinical trial","volume":"661","author":"Denis","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107340_bib0009","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3390\/pharmaceutics15061642","article-title":"Characterization and validation of a new 3D printing ink for reducing therapeutic gap in pediatrics through individualized medicines","volume":"15","author":"D\u00edaz-Torres","year":"2023","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejps.2025.107340_bib0011","unstructured":"EMA, 2025. Quality innovation group (QIG) listen and learn Focus Group (LLFG) meeting on personalised medicines | European medicines agency (EMA) [WWW Document]. URL https:\/\/www.ema.europa.eu\/en\/events\/quality-innovation-group-qig-listen-learn-focus-group-llfg-meeting-personalised-medicines (accessed 8.13.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0012","unstructured":"EMA, 2006. Formulations of choice for the paediatric population - scientific guideline | European medicines agency (EMA) [WWW Document]. URL https:\/\/www.ema.europa.eu\/en\/formulations-choice-paediatric-population-scientific-guideline (accessed 8.13.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0015","series-title":"3D Printing of Pharmaceuticals, AAPS Advances in the Pharmaceutical Sciences Series","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-3-319-90755-0_7","article-title":"The role of semi-solid extrusion printing in clinical practice","author":"Firth","year":"2018"},{"key":"10.1016\/j.ejps.2025.107340_bib0016","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1021\/acs.molpharmaceut.4c00032","article-title":"Quality by design considerations for drop-on-demand point-of-care pharmaceutical manufacturing of precision medicine","volume":"21","author":"Forbes","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2025.107340_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118497","article-title":"Automated therapy preparation of isoleucine formulations using 3D printing for the treatment of MSUD: first single-centre, prospective, crossover study in patients","volume":"567","author":"Goyanes","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107340_bib0018","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1089\/3dp.2020.0076","article-title":"Uncertain but not unregulated: medical product regulation in the light of three-dimensional printed medical products","volume":"7","author":"Horst","year":"2020","journal-title":"3D. Print. Addit. Manuf."},{"key":"10.1016\/j.ejps.2025.107340_bib0019","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3390\/pharmaceutics15071877","article-title":"Practical application of 3D printing for pharmaceuticals in hospitals and pharmacies","volume":"15","author":"Huanbutta","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107340_bib0020","unstructured":"ICH, 2013. ICH Q11 development and manufacture of drug substances (chemical entities and biotechnological\/biological entities) - scientific guideline | European medicines agency (EMA) [WWW Document]. URL https:\/\/www.ema.europa.eu\/en\/ich-q11-development-manufacture-drug-substances-chemical-entities-biotechnological-biological-entities-scientific-guideline (accessed 8.11.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0021","unstructured":"ICH, 2009. ICH Q8 (R2) pharmaceutical development - scientific guideline | European medicines agency (EMA) [WWW Document]. URL https:\/\/www.ema.europa.eu\/en\/ich-q8-r2-pharmaceutical-development-scientific-guideline (accessed 8.11.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0022","unstructured":"ICH, 2008. ICH Q10 pharmaceutical quality system - scientific guideline | European medicines agency (EMA) [WWW Document]. URL https:\/\/www.ema.europa.eu\/en\/ich-q10-pharmaceutical-quality-system-scientific-guideline (accessed 8.11.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0023","unstructured":"ICH, 2006. ICH Q9 quality risk management - scientific guideline | European medicines agency (EMA) [WWW Document]. URL https:\/\/www.ema.europa.eu\/en\/ich-q9-quality-risk-management-scientific-guideline (accessed 8.11.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0024","unstructured":"ICH Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances - scientific guideline | European Medicines Agency (EMA) [WWW Document], 1999. URL https:\/\/www.ema.europa.eu\/en\/ich-q6a-specifications-test-procedures-acceptance-criteria-new-drug-substances-new-drug-products-chemical-substances-scientific-guideline (accessed 10.13.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0025","first-page":"24","article-title":"Entering new domains for 3D printing of drug products","volume":"49","author":"J\u00f8rgensen","year":"2025","journal-title":"Pharm. Techn."},{"key":"10.1016\/j.ejps.2025.107340_bib0026","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12247-024-09889-9","article-title":"Design of a pharmaceutical 3D printer using quality-by-Design approach","volume":"19","author":"Lafeber","year":"2024","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.ejps.2025.107340_bib0027","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/children10010147","article-title":"Drug prescriptions requiring compounding at a Canadian University affiliated pediatric hospital: a cross-sectional study","volume":"10","author":"Landry","year":"2023","journal-title":"Children"},{"key":"10.1016\/j.ejps.2025.107340_bib0028","unstructured":"Pew, 2022. FDA\u2019s regulatory framework for 3D printing of medical devices at the point of care needs more clarity [WWW Document]. URL https:\/\/pew.org\/3zkHsSS (accessed 8.13.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125581","article-title":"Clinical implementation of a paediatric 3D-printed combination of sulfamethoxazole and trimethoprim","volume":"676","author":"Stoops","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107340_bib0031","unstructured":"USP, 2025. 2020\u20132025 Compounding expert committee work Plan | USP [WWW Document]. URL https:\/\/www.usp.org\/expert-committees\/compounding-expert-committee-work-plan (accessed 8.13.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0032","unstructured":"USP, 2022. <1220>, Analytical procedure life cycle."},{"key":"10.1016\/j.ejps.2025.107340_bib0033","unstructured":"USP, 2020. Four-day series on quality of 3D printing of medicines and supplements July 13-16 [WWW Document]. URL https:\/\/www.usp.org\/news\/3d-printing-workshop (accessed 8.13.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0034","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/pharmaceutics15010028","article-title":"The quest for child-friendly carrier materials used in the 3D semi-solid extrusion printing of medicines","volume":"15","author":"Van Kampen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107340_bib0035","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3390\/pharmaceutics15030840","article-title":"Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: a review","volume":"15","author":"Yuliani","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107340_fur1","unstructured":"FDA, C. for D. and R., 2020. Technical considerations for additive manufactured medical devices [WWW Document]. URL https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/technical-considerations-additive-manufactured-medical-devices (accessed 8.13.25)."},{"key":"10.1016\/j.ejps.2025.107340_bib0029","unstructured":"Quality Innovation Group (QIG) Listen and learn Focus Group (LLFG) meeting on personalised medicines | European Medicines Agency (EMA) [WWW Document], 2025. URL https:\/\/www.ema.europa.eu\/en\/events\/quality-innovation-group-qig-listen-learn-focus-group-llfg-meeting-personalised-medicines (accessed 10.12.25)."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T19:21:35Z","timestamp":1766776895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725003380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"alternative-id":["S0928098725003380"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107340","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A risk-based, QTPP-driven framework for semi-solid extrusion 3d printing of personalized medicines: Integrating hospital compounding and clinical trial regulation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107340"}}